505 IGSF8 is a novel innate immune checkpoint and cancer immunotherapy target

• Bin Xie,
• Yulong Li,
• Karim A Benhadji,
• X Shirley Liu,
• Xiangyang Wu,
• Hailing Liu,
• Xi Xiao,
• Huizhu Liu,
• Qingyang Ding,
• Caibin Sheng,
• Rongbin Zheng,
• Quan Yu,
• Xihao Hu,
• Tengfei Xiao

Affiliations

Bin Xie

2GV20 Therapeutics, Shanghai, China

Yulong Li

Center of Genome and Personalized Medicine, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, Liaoning, China

Karim A Benhadji

Eli Lilly and Company, New York, New York, USA

X Shirley Liu

1Dana-Farber Cancer Institute, Boston, MA, United States

Xiangyang Wu

2GV20 Therapeutics, Shanghai, China

Hailing Liu

2GV20 Therapeutics, Shanghai, China

Xi Xiao

2GV20 Therapeutics, Shanghai, China

Huizhu Liu

2GV20 Therapeutics, Shanghai, China

Qingyang Ding

2GV20 Therapeutics, Shanghai, China

Caibin Sheng

1GV20 Therapeutics, Cambridge, MA, USA

Rongbin Zheng

2GV20 Therapeutics, Shanghai, China

Quan Yu

2GV20 Therapeutics, Shanghai, China

Xihao Hu

1GV20 Therapeutics, Cambridge, MA, USA

Tengfei Xiao

2GV20 Therapeutics, Shanghai, China